



## **TIRmed Pharma appoints Peder Walberg to the board – strengthens position ahead of clinical phase**

**Sciety's portfolio company TIRmed Pharma has strengthened its board with the appointment of Peder Walberg – a strategic addition as the company advances the development of a promising new treatment for atopic dermatitis (eczema). The appointment is the result of a targeted recruitment process carried out in close collaboration between TIRmed and Sciety, where Walberg's experience was seen as particularly valuable in preparation for the company's upcoming Phase Ib clinical trial.**



TIRmed is developing a next generation treatment for atopic dermatitis, with the ambition to offer patients an effective therapy with fewer side effects and easier administration.

Unlike existing therapies that mainly relieve symptoms, TIRmed's treatment targets the underlying causes of the disease. Preclinical results have been highly promising – just five applications over two weeks have delivered relief lasting up to 15 months. The addition of Peder Walberg strengthens the board at a critical time, as TIRmed prepares to enter clinical trials.

Peder Walberg is a licensed physician and economist, currently active as an investor and advisor in the life science sector. He also serves on the board of Immedica Pharma AB. Walberg brings a long and accomplished career in life sciences, with extensive experience in driving drug development and commercialisation. During his time at Novartis, he was responsible for the Swedish launch of Elidel, a treatment for atopic dermatitis. He has played key roles in strategic decision-making, regulatory considerations, and negotiations with licensing partners and acquirers. His previous roles include senior positions at Sobi, Wilson

Therapeutics, Immedica Pharma AB, and Egetis Therapeutics.

The board recruitment was carried out by TIRmed in close dialogue with Society, who identified Walberg as a strong candidate to support both the clinical development of the company's drug candidate and its broader strategic and commercial progress.

"We are very pleased to welcome Peder Walberg to the board. His experience in building value in pharmaceutical companies – from clinical development through to market launch – will be invaluable to TIRmed as we move into our upcoming clinical trial," says Leo Holmgren, CEO of TIRmed Pharma.

"Peder Walberg brings experience that complements the existing board in a highly valuable way. His strategic and commercial expertise is particularly important at this stage of the company's journey – where making the right decisions around study design and regulatory strategy will lay the foundation for strong positioning and future commercialisation. Helping to identify the right board expertise is a key part of how we at Society work in close partnership with our portfolio companies," says Andreas Lindblom, Managing Partner at Society.

The appointment of Peder Walberg strengthens TIRmed's board both operationally and strategically, and marks an important step in the company's preparations for further clinical studies and future commercialisation.

**For further information, please contact:**

Andreas Lindblom, Managing Partner, Society: [andreas.lindblom@society.se](mailto:andreas.lindblom@society.se), phone: +46 70 375 73 73

Leo Holmgren, CEO, TIRmed Pharma, [leo.holmgren@tirmedpharma.com](mailto:leo.holmgren@tirmedpharma.com), phone: +46 70 049 18 42

**About TIRmed Pharma**

TIRmed Pharma is a biotechnology company developing the next generation of immunomodulatory treatments for autoimmune skin diseases, with a focus on atopic dermatitis (eczema). The company's drug candidate, TIR-C, is a topical oligonucleotide-based treatment that regulates the immune system and addresses the underlying causes of the disease. Preclinical results demonstrate the treatments potential to provide long-lasting relief and reduce treatment burden. TIRmed Pharma is headquartered in Stockholm. For more information, visit [tirmedpharma.com](http://tirmedpharma.com) and follow TIRmed on [LinkedIn](#).

**About Society**

Society is a leading investment company, committed to supporting the growth of innovative life science and health tech companies in the Nordic region. We invest alongside Society Venture Partners, comprising family offices and private investors, as well as venture capital firms. Our mission is to enable the full potential of life science innovations, helping to bring breakthroughs in healthcare to people all over the world. For more information visit [society.com](http://society.com) and follow Society on [LinkedIn](#).